These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32536937)

  • 1. Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges.
    Green SD; Konig H
    Front Genet; 2020; 11():480. PubMed ID: 32536937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours.
    Molica M; Perrone S
    Expert Rev Hematol; 2022 Nov; 15(11):973-986. PubMed ID: 36271671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment.
    Peroni E; Randi ML; Rosato A; Cagnin S
    J Exp Clin Cancer Res; 2023 Oct; 42(1):259. PubMed ID: 37803464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects.
    Gambacorta V; Gnani D; Vago L; Di Micco R
    Front Cell Dev Biol; 2019; 7():207. PubMed ID: 31681756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia.
    Wingelhofer B; Somervaille TCP
    Front Oncol; 2019; 9():850. PubMed ID: 31552175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.
    Konig H; Santos CD
    Curr Cancer Drug Targets; 2015; 15(9):803-21. PubMed ID: 26278711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells.
    Gadhoum Z; Delaunay J; Maquarre E; Durand L; Lancereaux V; Qi J; Robert-Lezenes J; Chomienne C; Smadja-Joffe F
    Leuk Lymphoma; 2004 Aug; 45(8):1501-10. PubMed ID: 15370200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches.
    Winer ES; Stone RM
    Ther Adv Hematol; 2019; 10():2040620719860645. PubMed ID: 31321011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in targeted therapies in acute myeloid leukemia.
    Bhansali RS; Pratz KW; Lai C
    J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure.
    Pasquer H; Tostain M; Kaci N; Roux B; Benajiba L
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S; Daver N; Ravandi F
    Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
    Miyamoto K; Minami Y
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
    Madanat YF; Kalaycio ME; Nazha A
    Acta Med Acad; 2019 Apr; 48(1):35-44. PubMed ID: 31264431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities.
    Zhao X; Liu HQ; Wang LN; Yang L; Liu XL
    Semin Cancer Biol; 2022 Aug; 83():121-135. PubMed ID: 33242577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
    Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
    Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment stratification by fitness for chemotherapy in acute myeloid leukemia].
    Morita Y
    Rinsho Ketsueki; 2022; 63(6):667-677. PubMed ID: 36184522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.
    Gallipoli P; Giotopoulos G; Huntly BJ
    Ther Adv Hematol; 2015 Jun; 6(3):103-19. PubMed ID: 26137202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
    Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.